Close menu




December 20th, 2021 | 12:56 CET

Manganese X Energy, Allkem, Nordex - Winners for 2022!

  • Investments
Photo credits: pixabay.com

Electromobility is a megatrend. The central challenges are efficient storage of emission-free, i.e. "green", produced electrical energy and the development of the corresponding infrastructure. Scientists and experts agree that raw materials such as copper, lithium, manganese, cobalt, silver and gold will be indispensable with increasing electrification.

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: MANGANESE X ENERGY | CA5626783008 , Allkem Ltd. | AU0000193666 , NORDEX SE O.N. | DE000A0D6554

Table of contents:


    Manganese X Energy - Disruption in the battery market?

    The Canadian explorer Manganese X Energy has ambitious goals. The Company is dedicated to exploring and developing domestic raw material deposits, which are indispensable in the production of rechargeable batteries. The focus is on nickel and cobalt elements, but mainly on the semimetal manganese. The graphite division was spun off a few months ago as Graphano Energy Ltd.

    "Manganese is a candidate for a game-changer in lithium-ion batteries. Manganese has elemental properties that have the potential to improve battery density, capacity, rechargeability, safety and longevity. The timing for developing a North American manganese deposit could not be better. Given the global drive for greener technology and reducing carbon footprints, Manganese X is positioned to be a leader in providing a domestic supply of manganese to the rechargeable battery industry. This includes small consumer batteries in electronic devices, smartphones and energy storage to the EV and hybrid electric vehicle industry," Martin Kepman, CEO of Manganese X Energy Corp, said in a recent interview.

    The Company operates the Battery Hill project in Woodstock in the province of New Brunswick, among other projects. The 1,228-hectare property consists of 55 claims of manganese-iron deposits and is the only commercially explored manganese deposit in North America. An initial official resource estimate suggests 34.86 million tonnes of proven manganese at a grade of 6.42%, with suspected resources at 25.91 million tonnes at a grade of 6.66%. The Company itself sees the resource potential at many times that amount.

    Over 80% of global manganese production comes from South Africa. The Canadians could shift this weight significantly in the medium term and also score points with their geographical proximity to the sales markets of North America. Experts forecast demand growth of 30% p.a. for the semimetal and rising prices in the coming years. With a market capitalization of CAD 37 million, the Company is moderately valued given its potential.

    Allkem - New name, new all-time high?

    Since the beginning of the month, Orocobre Limited is now called Allkem Limited. It was preceded by the merger with Galaxy Resources to become what is now the fifth-largest lithium producer in the world. Allkem is a global supplier of lithium carbonate and a producer of boron. The Company primarily focuses on the operational lithium business and the development of lithium deposits in Argentina.

    Allkem is currently valued at AUD 5.8 billion. The stock is trading about 10% below its all-time high, but rising prices are only a matter of time given the excellent underlying conditions. Lithium will remain one of the most important raw materials for the production of rechargeable batteries for the foreseeable future. Due to rising demand, the price of battery-grade lithium carbonate has already more than quadrupled this year alone. And there is no end in sight. According to estimates by raw materials giant Rio Tinto, only 15% of the supply deficit will be covered by existing projects in the next 10 years. Therefore, it is not surprising that the analyst consensus rates the shares as a "buy". After the excellent share performance in recent months, the upside potential is only around 14%. The stock is accorded relatively high P/E ratios, but these should soon be put into perspective by dynamic growth. The 2022 P/E ratio is 29 and falls to 23 for 2023.

    Nordex - Another significant order received

    The political framework conditions for green energy production are favorable. As one of the leading integrated, globally positioned manufacturers of innovative onshore wind turbines, Nordex should also benefit from these prospects. However, this has not been reflected in the share price performance in recent months. Even the significant order recently placed by the Norwegian Company Statkraft, Europe's largest producer of renewable energies, for the delivery of 19 N163/5.X turbines for Chile was unable to provide any impetus for higher share prices. Since April, the shares of the North German Company have almost halved in value, with the current stock market value now standing at around EUR 2.3 billion. Most analysts rate the stock as a "buy" and calculate an average upside potential of a good 30%.


    Battery metals, in particular, are indispensable for electromobility and difficult to replace by other materials. The high demand for certain raw materials in the face of limited supply should mean higher prices in the medium term. Thus, Allkem should be on the winning side as a producer. The same applies to Manganese X Energy. The Company is more speculative due to its young company phase but has a high potential due to the excellent project quality and the moderate valuation. Nordex should benefit from the general growth of green energy.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read